# Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

> **NCT04096690** · PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 22 (estimated)

## Conditions studied

- Nasal Type Extranodal NK/T-Cell Lymphoma

## Interventions

- **DRUG:** Pegaspargase
- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT04096690
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-10
- **Primary completion:** 2021-12
- **Final completion:** 2022-12
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2020-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04096690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04096690, "Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04096690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*